Nina Thomas, MD
Pulmonary Disease · Aurora, CONPI 1750624466
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (31.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 79.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $6,277 and has fallen 52.0% since, to $3,014 in 2025.
Across 47 payments — averaging $301.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Johnson & Johnson$150
- Siemens Medical Solutions USA, Inc.$138
- Boston Scientific$95
- Corcept Therapeutics$39
- plus $16 from 1 others
What the payments were for
- Consulting fees$2,54318%
- Speaking & faculty fees$3,00021%
- Travel & lodging$2,79920%
- Food & beverage$1,3469%
- Education$4,50032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 41 | $11,207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,543 |
| Johnson & Johnson | 1 | $150 |
| Siemens Medical Solutions USA, Inc. | 1 | $138 |
| Boston Scientific | 1 | $95 |
| Corcept Therapeutics | 1 | $39 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,419
- DA VINCI SP$3,000
- ALUNBRIG$2,543
- Certus 140$150
How this compares
$14,188 in reported general payments places this provider in the 85th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Incruse ElliptaUmeclidinium Bromide | 21 | $9,971 |
| Spiriva HandihalerTiotropium Bromide | 11 | $9,292 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $274 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Aurora
- David SchwartzAurora$471K
- David BadeschAurora$134K
- Robert WinnAurora$70K
- Richard AlbertAurora$64K
- Joyce LeeAurora$63K
- Kevin DavidsonAurora$19K
- Melanie KoenigshoffAurora$15K
- Raymond ParrishAurora$14K
- Brian GrahamAurora$14K
- Michael WechslerDenver$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.